

# Biologics & Vaccine Innovation Platforms

Building on 35 Years of Scientific Expertise and Innovation

## End-to-End Solutions for Biologics and next generation Vaccines

iBET supports biologics and vaccine programs from candidate design to clinical ready material. We combine molecular design, cell line and substrate development, upstream and downstream intensification, and analytical depth into tailored workflows to bring complex protein, multi-specific monoclonal antibodies, virus-like particles (VLPs) and viral antigen-based products closer to the clinic.



### What We Offer

- > Scalable, industry aligned biologics & vaccine development platforms, integrating molecular engineering, cell line development (CLD), and upstream-downstream bioprocessing.
- > Over 35 years of bioprocess and analytical expertise to deliver robust, manufacturable solutions across recombinant proteins, antibodies, viral antigens, VLPs, and nanoparticle vaccines.



### Why Work With Us?

- > Proven track record with global biotherapeutics and vaccine programs.
- > Broad expertise across antibodies, complex recombinant proteins, viral antigens, VLPs, and nanoparticle platforms.
- > Troubleshooting productivity, manufacturability, and quality across the process chain.
- > Decision ready data and realistic timelines supporting biologics & vaccine developers.



### Application for Pharma, Biotech & Vaccine Developers

- > Enhance manufacturability, scalability & CQA-driven quality for mAbs, multispecific & other Abs formats, and complex recombinant proteins.
- > Develop high-performance cell lines and scalable USP/DSP workflows for viral antigens, VLPs & nanoparticle vaccines.
- > Strengthen vaccine performance through immunogenicity, structural-integrity & advanced analytical assessments.
- > Advance emerging RNA-enabled & hybrid nanoparticle platforms with in-depth particle characterization & functional cell-based assays.



### What Makes iBET Different

- > Integration of cell line development + USP + DSP + analytics within a single Partner Research Organization.
- > Intensified upstream strategies (perfusion, microcarriers) and continuous DSP.
- > Depth in VLP and nanoparticle vaccine engineering, ferritin-based antigen display, and viral antigen expression systems.
- > Multi omics and MS based characterization for early CMC aligned decisions.
- > Long standing collaborations with pharma and biotech in biologics and vaccine development.

## How can we work together?

- > Feasibility studies on manufacturability & process risks
- > Molecular design, vector construction, and stable cell line development
- > USP/DSP development for antibodies, proteins, antigens and VLPs
- > Analytical development, CQAs & comparability, potency & MoA assays
- > Tech transfer preparation toward pilot and GMP partners



[Check our toolboxes for scientific insights and data](#)